MedWatch

Novo and Coloplast among the world’s most innovative companies

A new analysis from renowned US business magazine, Forbes, places Novo Nordisk and Coloplast among the 100 most innovative companies in the world.

Important US business magazine, Forbes, has crafted a list of the 100 most innovative companies on which the Danish medtech and pharma industry features prominently.

Coloplast makes it to number 12, and further down the list at number 70 diabetes giant Novo Nordisk is found.

The list is based on a so-called innovation premium, defined as “a measure of how much investors have bid up the stock price of a company above the value of its existing business based on expectations of future innovative results (new products, services and markets),” the magazine writes.

Moreover, companies on the list must have $10 billion in market capitalization, spend at least 2.5% of revenue on R&D and have seven years of public data.

In this regard, Coloplast and Novo scores an innovation premium of 46,5 % and 23,4 % respectively.

Life science fairs well

Generally speaking, the life science industry fairs well on Forbes’ innovation list. Two biotech companies, Alexion Pharmaceuticals (2) and Regeneron Pharmaceuticals (4), make it into the top 5.

Further down the list the medtech and pharmaceutical industries are represented by major corporations like Smith & Nephew (51), Valeant Pharmaceuticals (62), Covidien (67) og Mylan (90).

The only other Danish company on the list aside from Coloplast and Novo is Carlsberg, which slots in at 66.

Novo Nordisk tops global top 25 of biotechs

Novo among the 100 most valuable companies in the world

See the complete list from Forbes here.

Want to receive the latest news from Medwatch straight in your e-mail inbox? Sign up for our free english newsletter below.

Frontpage right now

Danmark får første bioteknotering siden 2010

For første gang siden Zealand Pharma gik på børsen i 2010, kommer der nu en dansk bioteknotering. Orphazyme har tirsdag indledt børsprocessen med den såkaldte intention-to-float til fondsbørsen.

Dommer bortkaster J&J-milliarddom

For anden gang på under en uge bliver en dom mod Johnson & Johnson i de såkaldte talkumsager nu omstødt. Denne gang handler det om en dom til 2,5 mia. kr.

Japansk medvind til dansk medicoopstart

Det danske opstartsselskab Medtrace har indgået et nyt samarbejde med et japansk industrikonglomorat, som skal hjælpe selskabet med den regulatoriske og kommercielle udvikling af hovedproduktet.

Latest Top picks in English

Related articles